Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01587430 | 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | unknown | Phase 4 | 245 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 7, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical School |
| 1 |
| Mar 26, 2014 |
| clinicaltrials |
| NCT02072811 | Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia(PALG-AML2012) | unknown | Phase 3 | 400 | dr hab. n. med. Agnieszka WierzbowskaOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT01280786 | Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 36 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Feb 3, 2014 | clinicaltrials |
| NCT01400074 | Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib(RE-NICE) | unknown | Phase 3 | 100 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01562847 | Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib(AMICAN) | unknown | — | 125 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01564836 | Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib | unknown | N/A | 50 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00242515 | T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | unknown | Phase 1 / Phase 2 | 16 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT02024308 | AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy | unknown | Phase 4 | 62 | Changhai HospitalOTHER | 1 | Dec 31, 2013 | clinicaltrials |
| NCT00451711 | Intermittent Liposomal Amphotericin B Primary Prophylaxis | unknown | Phase 2 | 60 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01488344 | Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 140 | University Hospital MuensterOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT01307241 | RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML | unknown | — | 50 | National Institute of CancerologíaOTHER_GOV | 1 | Nov 15, 2013 | clinicaltrials |
| NCT01188330 | Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival(MLSP) | unknown | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Oct 31, 2013 | clinicaltrials |
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT01901666 | Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission | unknown | Phase 4 | 20 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT01887561 | Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | unknown | Phase 2 | 100 | Kanto CML Study GroupOTHER | 1 | Jun 27, 2013 | clinicaltrials |
| NCT01503502 | A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | unknown | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
| NCT01809392 | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 2 / Phase 3 | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00636922 | Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 40 | Bayside HealthOTHER_GOV | 1 | Feb 15, 2013 | clinicaltrials |
| NCT01785953 | Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia(AML) | unknown | — | 300 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01766375 | the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient(IDBUCY) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 11, 2013 | clinicaltrials |
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | unknown | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT01615757 | Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation(Ara-c) | unknown | Phase 3 | 180 | All India Institute of Medical SciencesOTHER | 1 | Sep 17, 2012 | clinicaltrials |
| NCT01037556 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | unknown | Phase 1 / Phase 2 | 50 | Proacta, IncorporatedINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT01633099 | Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients | unknown | Phase 3 | 46 | Jianxiang WangUNKNOWN | 0 | Jul 6, 2012 | clinicaltrials |
| NCT01627132 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | unknown | Phase 2 | 50 | Shimousa Hematology Study GroupOTHER | 1 | Jun 25, 2012 | clinicaltrials |
| NCT00111345 | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | unknown | Phase 2 / Phase 3 | 550 | University Hospital MuensterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00887042 | Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML | unknown | Phase 1 / Phase 2 | 35 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Mar 26, 2012 | clinicaltrials |
| NCT01556477 | The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). | unknown | Phase 2 | 72 | Nordic MDS GroupNETWORK | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00445822 | Registration of Children With CML and Treatment With Imatinib(CML-paed II) | unknown | — | 150 | Technische Universität DresdenOTHER | 1 | Feb 29, 2012 | clinicaltrials |
| NCT01534702 | Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML(CIARA) | unknown | Phase 1 / Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01180426 | Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 30 | Chroma TherapeuticsINDUSTRY | 1 | Feb 15, 2012 | clinicaltrials |
| NCT01513109 | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia(ASCI) | unknown | Phase 1 / Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | New York Medical CollegeOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01464411 | Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan(D-First) | unknown | — | 40 | Kanto CML Study GroupOTHER | 1 | Nov 3, 2011 | clinicaltrials |
| NCT01423175 | ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS(ClAraC-SCT) | unknown | Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT01414231 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a(OSHO#061) | unknown | Phase 3 | 850 | University of LeipzigOTHER | 1 | Aug 11, 2011 | clinicaltrials |
| NCT01141673 | Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia | unknown | — | 100 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT01329471 | Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) | unknown | — | 75 | Hillel Yaffe Medical CenterOTHER_GOV | 1 | Apr 6, 2011 | clinicaltrials |
| NCT01315925 | Pre-hospital Risk Factors for Invasive Fungal Infection(SEIFEM 2010) | unknown | — | 1,000 | Catholic University of the Sacred HeartOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT01066494 | A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 20 | Antisoma ResearchINDUSTRY | 2 | Jan 17, 2011 | clinicaltrials |
| NCT01220544 | Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells | unknown | Phase 1 / Phase 2 | 30 | Charite University, Berlin, GermanyOTHER | 1 | Oct 14, 2010 | clinicaltrials |
| NCT00715637 | Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study | unknown | Phase 3 | 420 | Antisoma ResearchINDUSTRY | 23 | Oct 13, 2010 | clinicaltrials |
| NCT01195506 | Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML) | unknown | — | 40 | Taipei Medical University WanFang HospitalOTHER | 1 | Oct 6, 2010 | clinicaltrials |
| NCT01133886 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure(DEC-MDS) | unknown | Phase 2 | 50 | King's College LondonOTHER | 1 | Sep 3, 2010 | clinicaltrials |
| NCT01146977 | Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)(CBF(+)AML) | unknown | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 22, 2010 | clinicaltrials |
| NCT01145846 | Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)(AIvsAD) | unknown | Phase 3 | 316 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 17, 2010 | clinicaltrials |
| NCT01142375 | Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells | unknown | — | 100 | Taipei Medical University WanFang HospitalOTHER | 0 | Jun 11, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2014source: clinicaltrials